drugset
drugset / Trial / NCT07618715

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715 ↗

Phase 1 Not yet recruiting 11 enrolled Neurodawn Pharmaceutical Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary goal of this clinical trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules and riluzole tablets in the US healthy adult participants after single oral administration under fasted condition. The secondary goal of the trial is to evaluate the safety and tolerability of Y-4 tablets, pregabalin capsules and riluzole tablets in the US healthy adult participants.

Timeline

Start
2026-06-30
Primary completion
2026-08-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg Oral
Subject Pregabalin Small molecule 112.5 mg Oral
Subject Riluzole Small molecule 28.125 mg Oral
Subject Riluzole Small molecule 50 mg Oral

Indications

No indication recorded.